Ironwood Pharmaceuticals
IRWD
195 hedge funds and large institutions have $2.36B invested in Ironwood Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 53 increasing their positions, 69 reducing their positions, and 12 closing their positions.
258% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 12
58% more capital invested
Capital invested by funds: $1.49B → $2.36B (+$870M)
27% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $8.93M
19% more funds holding
Funds holding: 164 → 195 (+31)
2.13% more ownership
Funds ownership: 111.03% → 113.16% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
23% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$11.2M |
| 2 |
Two Sigma Investments
New York
|
+$11M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$9.8M |
| 4 |
D.E. Shaw & Co
New York
|
+$8.79M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$21.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$14M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$6.99M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.8M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.58M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SL
201
Signition LP
New York
| – | -$100K | -11,664 | Closed |
|
202
Capital Fund Management (CFM)
Paris,
France
| – | -$95K | -11,100 | Closed |
|
|
PP
203
Paloma Partners
Greenwich,
Connecticut
| – | -$86K | -10,056 | Closed |
|
204
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$1K | -171 | Closed |
|
|
SPIA
205
Steward Partners Investment Advisory
New York
| – | -$11 | -1 | -33% |
|
IRWD Hedge Fund Activity: Q4 2019 in Review
195 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2019, worth a combined $2.36B — up 58% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new IRWD positions and 12 closed out — a net gain of 31 holders — while 53 added to existing stakes and 69 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $11.2M. The largest seller was UBS AM, cutting an estimated $21.1M.
- 195 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2019, up from 164 in Q3 2019.
- Funds reported $2.36B of Ironwood Pharmaceuticals stock for Q4 2019, up 58% quarter-over-quarter.
- 43 funds opened new Ironwood Pharmaceuticals positions in Q4 2019 and 12 closed out, a net change of +31 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2019 was Two Sigma Advisers, an estimated $11.2M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2019 was UBS AM, an estimated $21.1M sold.
Based on aggregated 13F filings for Q4 2019.